

CardioComm Solutions, Inc. Announces Grant of Stock Options

Victoria, B.C., September 19, 2008 – CardioComm Solutions, Inc. (TSX-V: EKG) (“CardioComm” or the “Company”) today announced that it has granted an aggregate of 2,675,000 incentive stock options to its directors, employees and consultants pursuant to its Omnibus Share Compensation Plan. The options are exercisable at \$0.12 per share for five years from the date of grant, will vest equally over a period of 18 months and are subject to a four month hold period. The grant of options will be subject to the provisions of the Company's Omnibus Share Compensation Plan, the policies of the TSX Venture Exchange and applicable securities laws.

In addition, CardioComm has negotiated to settle \$75,000 of outstanding debt of the Company in exchange for the issuance of 714,285 common shares of the Company (at a deemed issue price of \$0.105 per share) to a creditor of the Company. The shares for debt transaction is subject to the approval of the TSX Venture Exchange.

About CardioComm Solutions, Inc.

CardioComm's patented and proprietary technology is used in products for the recording, viewing, analyzing and storing of electrocardiograms (EKGs), for diagnosis and management of cardiac patients. The Company's products are sold worldwide through a combination of its external distribution network and its North American based sales team. CardioComm has achieved its technical goals of improved access and communication through the development of a real-time EKG viewer. CardioComm is the first company to provide a real-time means of viewing EKGs over a network (LAN, WAN or Internet). This tool enables EKGs to be viewed and controlled live, by physicians, over a global virtual healthcare network. This technology is marketed as Global EKG Management System (GEMS(TM)) and GlobalCardio(TM). CardioComm's software products have been cleared for sale in the United States by the U.S. Food and Drug Administration. The Company has earned the latest ISO 13485 certification.

On behalf of the Board of Directors of CardioComm Solutions, Inc.

“Anatoly Langer”

Dr. Anatoly Langer, Chairman

For investor information, please contact:

Ian Klassen

1-877-744-1122

www.cardiocomm.com

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.